The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Young Li - Jefferies - Analyst
: Thanks a lot, Bobby. So my name is Young Li, one of the analysts here at Jefferies. We'll just do some more follow-up Q&A.
And I guess just in terms of the (inaudible) that's coming up, I was wondering if you can comment on how some of the interactions been with the
FDA? Anything surprising? Is everything going according to plan?
Question: Young Li - Jefferies - Analyst
: All right. Well, you sound very confident. That's good. So I guess then maybe just on the investor update upcoming. Can we maybe get a preview
on what you're going to be focused on, what you might quantify at that event?
Question: Young Li - Jefferies - Analyst
: I guess some in terms of just the TAM and patient sizing, there's a lot of assumptions in there starting now with 25 million in the US. I was maybe
wondering if you can comment on some of the subcategories around dry eye and cataracts and how confident you are with those type of sizing
assumptions?
Question: Young Li - Jefferies - Analyst
: So I guess ahead of the (inaudible), you have the sales force infrastructure in place. You got a VP of Sales, regional directors, district managers. You
talked about 100 plus sales reps needed to support the launch. Maybe you can comment a little bit about where you're hiring them, how experienced
they are.
Question: Young Li - Jefferies - Analyst
: All right. Great. And then I guess in terms of education, I think you talked about the 10,000 plus optometrists and ophthalmologists. I guess, what
is the pace of the outreach, the education efforts? How many of the health care professionals can you reach annually?
Question: Young Li - Jefferies - Analyst
: Excellent. What about the on the reimbursement strategy team? Maybe talk a little bit about that as well as on the pricing for the product.
Question: Young Li - Jefferies - Analyst
: Great. Looking forward to that. So I guess you are much more than just a DB company. You talked about some of the pipeline during the presentation.
I guess maybe if you can comment a little bit, give us some updates about maybe Lyme disease, and MGD, and those type of trials?
Question: Young Li - Jefferies - Analyst
: All right. Great. And then, you have around $200 million in cash on the balance sheet. And I guess can you comment on maybe the burn rate as
you commercialize? And now how do you feel about your cash position right now?
Question: Young Li - Jefferies - Analyst
: Great. I guess maybe I'll pause here and open it up for the audience if anyone has any questions.
Unidentified Participant
Any plans for Europe (technical difficulty)
Question: Young Li - Jefferies - Analyst
: Anyone else from the audience? I guess maybe just kind of a catch-all question. Just kind of wondering, what's most misunderstood or most under
the radar about Tarsus?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JUNE 07, 2023 / 6:30PM, TARS.OQ - Tarsus Pharmaceuticals Inc at Jefferies Healthcare Conference
Question: Young Li - Jefferies - Analyst
: Great. I guess any final comments before we end here?
Question: Young Li - Jefferies - Analyst
: Great. Thank you so much. Looking forward to having you back next year.
| 
